Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately—authors’ reply

Bunchorntavakul, Chalermrat; Reddy, K. Rajender

doi:10.1111/apt.16581

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is not clear whether the authors used computed tomography (CT)-based skeletal muscle index (SMI) with liver-specific cutoffs to diagnose sarcopenia, whereas the Liver Frailty Index (LFI), which is specific to physical frailty, may be particularly useful for screening and follow-up in the ambulatory setting. 12 Although it is well-known that sarcopenia and frailty are associated with higher mortality risk, we herein explore the impact of two complications combined on long-term mortality by using our validated measurement and diagnostic criteria in a well-established cohort of hospitalized patients with cirrhosis.…”

Section: Introductionmentioning

confidence: 99%

Sarcopenia and frailty combined increases the risk of mortality in patients with decompensated cirrhosis

Guo

Hui

et al. 2022

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: Both sarcopenia and frailty are prevalent in patients with decompensated cirrhosis and associated with negative outcomes. However, few studies investigated the impact of their coexistence on mortality. We aimed to evaluate the role of sarcopenia and frailty on survival in a cohort of hospitalized cirrhotics. Methods: This was an observational cohort study including 221 patients hospitalized for decompensated events. The cutoff for low skeletal muscle index (SMI) at the third lumbar vertebra level on computed tomography built by our previous work (male: SMI <46.96 cm2/m2; female: SMI <32.46 cm2/m2) was used for the diagnosis of sarcopenia. Individuals with a Frailty Index >0.38 were considered frail. The sample was divided into four groups: sarcopenia and frailty (SF); sarcopenia and non-frailty (SN); non-sarcopenia and frailty (NF); and non-sarcopenia and non-frailty (NN). Follow-up for survival lasted 2 years. Results: Sarcopenia and frailty were present in 21.7% and 14.5% of the patients, respectively. The frequency of frailty in the group of sarcopenic patients was significantly higher than in the patients without sarcopenia (27.1% versus 11%, p = 0.009). In the survival analysis, the SF group showed a higher hazard ratio (2.604 in model 1; 4.294 in model 2) for mortality when compared with the NN group. In addition, the concurrence of those two conditions does give rise to incremental risk for mortality when compared with the group with each disturbance separately, namely, the SN/NF group. Conclusion: In conclusion, cirrhotic patients with sarcopenia and frailty combined showed higher mortality risk.

show abstract

Section: Introductionmentioning

confidence: 99%

Sarcopenia and frailty combined increases the risk of mortality in patients with decompensated cirrhosis

Guo

Hui

et al. 2022

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately—authors’ reply

Abstract: LINKED CONTENTThis article is linked to Bunchorntavakul & Reddy and Alexopoulos et al papers. To view these articles, visit https://doi.org/10.1111/apt.15571 and https://doi.org/10.1111/apt.16564

Cited by 1 publication

References 9 publications

Sarcopenia and frailty combined increases the risk of mortality in patients with decompensated cirrhosis

Sarcopenia and frailty combined increases the risk of mortality in patients with decompensated cirrhosis

Contact Info

Product

Resources

About